Acute myeloid leukemia: open trials in Austria

14 open trials have a site in Austria. Registry data; only the trial team decides who can take part.

NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH, Feldkirch · Ordensklinikum Linz GmbH, Linz · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-11-06
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Trial Treatment · Phase 3 · University of Ulm
Tirol Kliniken GmbH, Innsbruck · Ordensklinikum Linz GmbH, Linz · Kepler Universitaetsklinikum GmbH, Linz · Landeskrankenhaus (LKH) Rankweil, Interne E am Landeskrankenhaus Rankweil, Rankweil · Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH, Salzburg · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-11-03
NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Kepler Universitatsklinikum GmbH, Linz · Ordensklinikum Linz GmbH Elisabethinen, Linz · Universitaetsklinikum Salzburg Landeskrankenhaus, Salzburg · Wiener Gesundheitsverbund - Klinik Hietzing, Vienna · Medical University of Vienna Universitatsklinik fur Innere Medizin I, Vienna · Klinikum Wels-Grieskirchen, Wels
Registry updated 2026-11-03
NCT07581002
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 2/3 · AbbVie
Medical University of Graz, Graz · Ordensklinikum Linz GmbH, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna · Medical University of Vienna, Vienna
Registry updated 2026-10-22
2024-512753-24-00
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH, Feldkirch · Medizinische Universitaet Innsbruck, Innsbruck · SCRI CCCIT Ges.m.b.H., Salzburg · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-10-21
NCT07211958
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Trial Treatment · Phase 3 · Syndax Pharmaceuticals
Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Landeskrankenanstalten-Betriebsgesellschaft Kabeg, Klagenfurt Am Woerthersee · Steiermaerkische Krankenanstalten Ges.m.b.H., Leoben · Ordensklinikum Linz GmbH, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Klinik Favoriten, Vienna
Registry updated 2026-10-21
NCT06376162
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Trial Treatment · Phase 1 · PedAL BCU, LLC
St. Anna Kinderspital GmbH, Vienna
Registry updated 2026-10-09
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
AKH Wien, Universitatsklinikum, Vienna
Registry updated 2026-09-15
NCT06652438
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH, Feldkirch · Kepler Universitaetsklinikum GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-09-02
2025-521390-14-00
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 2 · Pediatric Research International GmbH
St. Anna Kinderspital GmbH, Vienna
Registry updated 2026-08-04
NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Trial Treatment · Phase 2 · Taiho Oncology, Inc.
Klinik Hietzing, Vienna
Registry updated 2026-07-28
NCT05907057
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Trial Treatment · Phase 3 · Servier Affaires Médicales
Ordensklinikum Linz GmbH, Linz · Medical University of Vienna, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-05-08
NCT01252485
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Research · University of Ulm
Medizinische Universität Graz, Graz · Medizinische Universität Innsbruck, Innsbruck · Krankenhaus der Elisabethinen Linz GmbH, Linz · Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H., Linz · Kepler Universitatsklinikum GmbH, Linz · Landeskrankenhaus Feldkirch, Rankweil · Universitätsklinikum der PMU Landeskrankenhaus Salzburg, Salzburg · Hanuschkrankenhaus Wien, Vienna
Registry updated 2026-01-05
NCT07075016
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
AT-Feldkirch-IKHF, Feldkirch · AT-Salzburg-SALK, Salzburg · AT-Vienna-HANUSCH, Vienna
Registry updated 2025-08-19

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error